Company profile for Ryvu Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in precision oncology. Ryvu Therapeuctis was founded in 2007 and currently employs 150 scientists, including 80 Ph.Ds. Ryvu was previously known as Selvita, until renamed to Ryvu Therapeutics after spin out of the services segment. The company is headquartered in Kraków, Poland...
Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in precision oncology. Ryvu Therapeuctis was founded in 2007 and currently employs 150 scientists, including 80 Ph.Ds. Ryvu was previously known as Selvita, until renamed to Ryvu Therapeutics after spin out of the services segment. The company is headquartered in Kraków, Poland. Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Poland
Address
Address
Bobrzyńskiego 14 30-348 Kraków, Poland
Telephone
Telephone
+48 12 297 46 90
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-12-11/ryvu-therapeutics-presents-new-clinical-data-from-river-81-and-potami-61-studies-of-romaciclib-rvu120-at-the-2025-american-society-of-hematology-as

PHARMIWEB
11 Dec 2025

https://www.pharmiweb.com/press-release/2025-11-05/ryvu-therapeutics-announces-three-abstracts-on-romaciclib-rvu120-and-one-abstract-on-dapolsertib-men1703-at-the-2025-american-society-of-hematolog

PHARMIWEB
05 Nov 2025

https://www.contractpharma.com/breaking-news/ryvu-therapeutics-to-support-clinical-trials-for-biontech-in-poland/

CONTRACTPHARMA
03 Sep 2025

https://www.prnewswire.com/news-releases/ryvu-therapeutics-announces-strategic-reorganization-to-extend-the-cash-runway-for-the-development-of-rvu120-and-the-preclinical-pipeline-302384585.html

PR NEWSWIRE
25 Feb 2025

https://www.prnewswire.com/news-releases/ryvu-therapeutics-provides-an-update-on-rvu120-phase-ii-program-302330063.html

PR NEWSWIRE
12 Dec 2024

https://www.prnewswire.com/news-releases/ryvu-therapeutics-announces-dosing-of-the-first-patient-in-the-potami-61-phase-ii-study-of-rvu120-for-the-treatment-of-patients-with-myelofibrosis-mf-302323665.html

PR NEWSWIRE
05 Dec 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty